

# WEDNESDAY SEPTEMBER 13, 2017

## PRECONFERENCE

7:15–8:00 **REGISTRATION AND BREAKFAST**

## RESIDENT REFRESHER COURSE *Convention Level – Toronto I*

8:00–4:00 Facilitator: Meredith Giuliani

OBJECTIVES: Upon completion of this refresher course, attendees should be able to:

- ▮ Give an evidence-based overview of the indications for brachytherapy for prostate, cervix, lung and esophageal cancers.
- ▮ Review the normal tissue tolerances, and acute and late side effects associated with various brachytherapy techniques.
- ▮ Explore emerging frontiers for the use of brachytherapy in cancer care.
- ▮ Develop skills in IMRT plan review and solving challenging image-guidance problems in clinical practice.

8:00–8:10 **WELCOME AND INTRODUCTIONS** Meredith Giuliani

8:15–9:15 **LDR PROSTATE BRACHYTHERAPY** Mira Keyes

9:15–10:15 **HDR BRACHYTHERAPY** Gerard Morton

10:15–10:30 **Break**

10:30–11:30 **CERVIX BRACHYTHERAPY** Israel Fortin

11:30–12:30 **HDR LUNG AND ESOPHAGEAL BRACHYTHERAPY** Ranjun Sur

12:30–1:30 **Lunch**

1:30–2:30 **PLAN LITERACY AND PRINCIPLES OF REVIEWING RT PLANS** John Kim

2:30–4:00 **CHALLENGING IGRT CASES AND HOW TO SOLVE THEM** Douglas Moseley, James Loudon

5:00 **Resident Social** (*off site*)

## EVOLVING TRENDS IN CANADIAN RADIATION ONCOLOGY *Toronto II*

9:30–4:00 Facilitator: Jennifer Croke

OBJECTIVES: For radiation oncologists to update and refresh their knowledge or skills in site-specific topics, particularly with Canadian content. It is important for maintenance of continuing education and lifelong learning. At the end of this session, participants will have reviewed:

- ▮ Current treatment techniques and planning, including contouring, specific margins, standard doses and fractionation.
- ▮ Latest in clinical trials.
- ▮ Effects of the combination of radiation therapy and new immunotherapy agents.
- ▮ Tips and tricks on how to solve challenging cases in IGRT.

9:30–9:40 **WELCOME AND INTRODUCTIONS** Jennifer Croke

9:40–10:10 **CNS- A NEW ERA OF RADIATION FOR SPINE AND BRAIN METASTASES** Arjun Sahgal, Mark Rushin

10:10–10:40 **BREAST** Anne Koch

10:40–11:00 **Break**

11:00–11:30 **PROSTATE** Andrew Loblaw

11:30–12:00 **TEACHING AN OLD DOG NEW TRICKS: HOW SHOULD RADIOTHERAPY BE COMBINED WITH IMMUNOTHERAPY DRUGS?** Scott Bratman

12:00–12:30 **SBRT** Laura Dawson

12:30–1:30 **Lunch**

1:30–2:00 **SARCOMA** Peter Chung

2:00–2:30 **Break** (*after break move to Toronto I*)

2:30–4:00 **CHALLENGING IGRT CASES AND HOW TO SOLVE THEM** Douglas Moseley, James Loudon

6:00–9:00 **CARO BOARD MEETING** *Governor General*

# THURSDAY SEPTEMBER 14, 2017

7:00–8:00	<b>MEET AND GREET</b> (invitation only) <i>Governor General</i>
	<b>REGISTRATION AND BREAKFAST</b> <i>Convention Level</i>
8:00–8:15	<b>WELCOME AND INTRODUCTIONS</b> – Fabio Cury, Eric Vigneault <i>Toronto I/II</i>
8:15–10:15	<b>THEME SYMPOSIUM</b> Moderator: Meredith Giuliani
	<b>Coming Soon! Competence by Design – What You Need to Know</b>
	OBJECTIVES: At the end of this session, the participants will be able to:
	<ul style="list-style-type: none"> <li>▮ Demonstrate an understanding of the context and rationale for competency based medical education (CBME).</li> <li>▮ Introduce what has been done in Radiation Oncology for Competence By Design (CBD).</li> <li>▮ Identify opportunities and challenges related to the implementation of CBD.</li> <li>▮ Identify assessment strategies in competency-based education.</li> <li>▮ Explore strategies to facilitate training in the CBD era.</li> </ul>
8:15-8:30	<b>WELCOME AND OVERVIEW OF CBME</b> Meredith Giuliani
8:30-9:00	<b>WHAT HAS BEEN DONE IN RADIATION ONCOLOGY</b> Theresa Trotter, Barbara-Ann Millar
9:00-9:20	<b>OPPORTUNITIES AND CHALLENGES</b> Brock Debenham
9:20-10:00	<b>PANEL AND STRATEGIES ON IMPLEMENTING COMPETENCE BY DESIGN</b> Joanne Alfieri, Sue Glover Takahashi, Paris-Ann Ingledew
10:00-10:15	<b>CLOSE AND NEXT STEPS</b> Meredith Giuliani, Barbara-Ann Millar
10:15–10:45	<b>Break</b>
10:45–11:45	<b>CARO LECTURE</b> Introduction: Eric Vigneault
	<b>Unlocking the Potential of Patient-Reported Outcomes</b>
	Claire Snyder
	OBJECTIVES: At the end of this session, the participants will be able to discuss the important, and somewhat unrealized, potential of patient-reported outcomes to improve the quality of cancer care at multiple levels, including at the patient-clinician interface, in clinical research, and for performance improvement.
11:45–1:45	<b>Lunch Break</b>
	<b>COMMITTEE MEETINGS</b> <i>Please refer to the Committee Meetings Schedule for exact times</i>
1:45-2:45	<b>ORAL SESSION 1 – BREAST CANCER</b> <i>Toronto I</i>
	Moderators: Sarah Hamilton, Alan Nicol
	OBJECTIVES: At the end of this session, the participants will be able to:
	<ul style="list-style-type: none"> <li>▮ Recognize important aspects of treatment planning and delivery for breast cancer.</li> <li>▮ Review current practices and outcomes of radiation therapy for breast tumours</li> </ul>
	<p><b>1 HEMATOPOETIC STEM CELL AND INFLAMMATORY CYTOKINE LEVELS ARE ASSOCIATED WITH FATIGUE AND INSOMNIA IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT RADIATION THERAPY</b> Fei-Fei Liu, Willa Shi, Megan McCusker, Justin Williams, J (Susie) Su, Tara Spence, Madeline Li, Wei Xu, Laleh S Ghorraie, Kathy Han, Scott Bratman, Kenneth Yip; Princess Margaret Cancer Centre, Toronto, ON</p>
	<p><b>2 LONG-TERM OUTCOMES OF MICROINVASIVE BREAST CANCER IN THE CANADIAN HYPOFRACTIONATION TRIAL</b> Mira Goldberg<sup>1</sup>, Sameer Parpia<sup>2</sup>, Eileen Rakovitch<sup>3</sup>, Laval Grimard<sup>4</sup>, Julie Bowen<sup>5</sup>, Himanshu Lukka<sup>2</sup>, Francisco Perera<sup>6</sup>, Anthony Fyles<sup>7</sup>, Timothy Whelan<sup>1</sup>; <sup>1</sup>Juravinski Cancer Centre, Hamilton, ON; <sup>2</sup>McMaster University, Hamilton, ON; <sup>3</sup>Odette Cancer Centre, Toronto, ON; <sup>4</sup>University of Ottawa, Ottawa, ON; <sup>5</sup>Northeastern Ontario Regional Cancer Centre, Sudbury, ON; <sup>6</sup>London Health Sciences Centre, London, ON</p>

**3 SIMPLE IMPLEMENTATION OF A DIBH TANGENTIAL IMRT TECHNIQUE FOR LEFT-SIDED BREAST CANCER** Dominique Mathieu, Nicolas Côté, Andrée-Anne Bernard, Noémie Lahaie, Stéphane Bedwani, Jean-François Aubry, David Roberge, Sophie Lavertu, Pierre Rousseau, Toni Vu; Université de Montréal, Montréal, QC

**4 ELEKTA FELLOWSHIP RADIATION THERAPY PRESCRIBING PATTERNS ACROSS 6 BREAST CANCER SCENARIOS** Theodora A Koulis<sup>1</sup>, Caroline Speers<sup>2</sup>, Jeremy Hamm<sup>2</sup>, Alexa Dang<sup>1</sup>, Josh Power<sup>1</sup>, Alan Nichol<sup>2</sup>, Scott Tyldesley<sup>2</sup>, Robert Olson<sup>2</sup>; <sup>1</sup>British Columbia Cancer Agency, Prince George, BC; <sup>2</sup>British Columbia Cancer Agency, Vancouver, BC

**5 ARE WE MISSING THE POST-OPERATIVE CAVITY IN WHOLE BREAST RADIOTHERAPY?** Grace Lee<sup>1</sup>, Felix Tsui<sup>1</sup>, Anne Koch<sup>1</sup>, Anthony Fyles<sup>1</sup>, Robert Dinniwel<sup>2</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>University of Western Ontario, London, ON

**6 SECOND CONSERVATIVE TREATMENT FOR BREAST CANCER LOCAL RECURRENCE USING HDR INTERSTITIAL BRACHY THERAPY: COSMETIC OUTCOME AND QUALITY OF LIFE** Marjory Jolicoeur<sup>1</sup>, Aly-Thiéman Diakité<sup>2</sup>, Talar Derashodian<sup>2</sup>, Maryse Mondat<sup>2</sup>; <sup>1</sup>Hopital Charles LeMoine CICM, Montréal, QC; <sup>2</sup>University of Sherbrooke, Longueuil, QC

1:45-2:45 **ORAL SESSION 2 – PALLIATIVE CARE** *Toronto II*

Moderators: Rashid Dar, Ericka Wiebe

**OBJECTIVES:** At the end of this session, the participants will be able to describe several important aspects involved in the decision-making process by radiation oncologists treating patients in need for palliative treatment.

**7 PALLIATIVE THORACIC RADIOTHERAPY IN ASYMPTOMATIC CENTRALLY LOCATED NON SMALL CELL LUNG CANCER (NSCLC) – TO TREAT OR TO DEFER** Anil Tibdewal<sup>1</sup>, Andrea Bezjak<sup>1</sup>, Lisa Le<sup>1</sup>, Kathy Pope<sup>2</sup>, Sarika Gill<sup>1</sup>, Joseph Nachman<sup>1</sup>, Andrew Hope<sup>1</sup>, Laura Dawson<sup>1</sup>, Rebecca Wong<sup>1</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

**8 ASSESSING THE UTILITY OF A PROGNOSTICATION MODEL TO PREDICT 1-YEAR MORTALITY IN PATIENTS RECEIVING RADIATION THERAPY FOR SPINAL METASTASES** Diana Shi<sup>1</sup>, Yu-Hui Chen<sup>2</sup>, Tai Chung Lam<sup>3</sup>, Dana Leonard<sup>2</sup>, Andrew Schoenfeld<sup>2</sup>, Tracy Balboni<sup>2</sup>, Sonia Skamene<sup>2</sup>, John Chi<sup>2</sup>, Marco Ferrone<sup>2</sup>, Charles Cho<sup>2</sup>, Mitchel Harris<sup>2</sup>, Lauren Hertan<sup>2</sup>; <sup>1</sup>Harvard Medical School, Boston, MA; <sup>2</sup>Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA; <sup>3</sup>The University of Hong Kong, Hong Kong

**9 BARRIERS TO REFERRAL FOR PALLIATIVE RADIOTHERAPY: A SYSTEMATIC REVIEW** Jonathan Klein<sup>1</sup>, Jonathan Livergant<sup>2</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>British Columbia Cancer Agency, Victoria, BC

**10 BEHAVIOURAL DETERMINANTS OF CANADIAN RADIATION ONCOLOGISTS' USE OF SINGLE FRACTION PALLIATIVE RADIATION THERAPY FOR UNCOMPLICATED BONE METASTASES** Kristopher Dennis<sup>1</sup>, Janet Squires<sup>1</sup>, Sarah Asad<sup>2</sup>, Kristin Dorrance<sup>2</sup>, Alysa Fairchild<sup>3</sup>, Edward Chow<sup>4</sup>, Rebecca Wong<sup>3</sup>, Ian Graham<sup>1</sup>, Jeremy Grimshaw<sup>1</sup>; <sup>1</sup>University of Ottawa, Ottawa, ON; <sup>2</sup>Ottawa Hospital Research Institute, Ottawa, ON; <sup>3</sup>University of Alberta, Edmonton, AB; <sup>4</sup>University of Toronto, Toronto, ON

**11 ASSESSING THE UTILITY OF THE SPINAL INSTABILITY IN NEOPLASIA (SINS) SCORE TO PREDICT FRACTURE AFTER CONVENTIONAL RADIATION THERAPY (RT) FOR SPINAL METASTASES** Diana Shi<sup>1</sup>, Lauren Hertan<sup>2</sup>, Tai Chung Lam<sup>3</sup>, Sonia Skamene<sup>2</sup>, John Chi<sup>2</sup>, Charles Cho<sup>2</sup>, Marco Ferrone<sup>2</sup>, Mitchel Harris<sup>2</sup>, Yu-Hui Chen<sup>2</sup>, Tracy Balboni<sup>2</sup>; <sup>1</sup>Harvard Medical School, Boston, MA; <sup>2</sup>Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA; <sup>3</sup>The University of Hong Kong, Hong Kong

**12 ARE PHYSICIANS FOLLOWING GUIDELINES? A REVIEW OF RADIATION ONCOLOGY PRACTICE IN PATIENTS WITH UNCOMPLICATED BONE METASTASES** Vanessa Di Lalla<sup>1</sup>, Bernard Fortin<sup>2</sup>, Catherine Pembroke<sup>1</sup>, Carolyn Freeman<sup>1</sup>, Michael Yassa<sup>2</sup>, Tarek Hijal<sup>1</sup>; <sup>1</sup>McGill University, Montreal, QC; <sup>2</sup>Hopital Maisonneuve Rosemont, Montreal, QC

2:45-3:45 **POSTER DISCUSSION SESSION 1** *Toronto I*

Moderators: Amanda Bolderston, Irene Karam

OBJECTIVES: At the end of this session, the participants will be able to discuss a variety of projects and research being conducted across the country in radiation oncology.

- |   |  |
|---|--|
| <p><b>13</b> <b>OBJECTIVE EVALUATION OF A STRUCTURED DIDACTIC RADIATION ONCOLOGY CLERKSHIP CURRICULUM: A REPORT FROM THE RADIATION ONCOLOGY EDUCATION COLLABORATIVE STUDY GROUP</b> Daniel Golden<sup>1</sup>, Greg Kauffmann<sup>1</sup>, Ryan McKillip<sup>1</sup>, Alan Schwartz<sup>2</sup>, Jeanne Farnan<sup>1</sup>, Yoon Soo Park<sup>2</sup>, Radiation Oncology Education Collaborative Study Group<sup>3</sup>; <sup>1</sup>University of Chicago, Chicago, IL; <sup>2</sup>University of Illinois at Chicago, Chicago, IL; <sup>3</sup>University of Illinois at Chicago, Chicago, IL</p> | <p><b>18</b> <b>AUTOMATED CONTOURING OF THE PROXIMAL BRONCHIAL TREE USING OPEN SOURCE TOOLS FOR SBRT TREATMENT OF THE LUNG</b> Niranjan Venugopal, Vijayananda Kundapur; University of Saskatchewan, Saskatoon, SK</p>   |
| <p><b>14</b> <b>A NEW FRONTIER: THE USE OF VIRTUAL SIMULATION FOR RADIATION THERAPY EDUCATION FOR BREAST CANCER PATIENTS</b> Jenny Soo<sup>1</sup>, Christina Parsons<sup>1</sup>, Christine Rodgers<sup>1</sup>, Jenny Seow<sup>1</sup>, Paris-Ann Ingledew<sup>2</sup>; <sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>University of British Columbia, Surrey, BC</p>   | <p><b>19</b> <b>ONLINE ADVERTISING AND MARKETING CLAIMS BY PROVIDERS OF PROTON BEAM THERAPY: ARE THEY GUIDELINE BASED?</b> Mark Corkum<sup>1</sup>, Wei Liu<sup>1</sup>, David Palma<sup>1</sup>, Robert Dinniwell<sup>1</sup>, Glenn Bauman<sup>1</sup>, Andrew Warner<sup>2</sup>, Mark Mishra<sup>3</sup>, Alexander Louie<sup>2</sup>; <sup>1</sup>University of Western Ontario, London, ON; <sup>2</sup>London Health Sciences Centre, London, ON; <sup>3</sup>University of Maryland School of Medicine, Baltimore, MD</p>  |
| <p><b>15</b> <b>PROSPECTIVE LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE AND SYMPTOMS IN PATIENTS WITH OLIGOMETASTATIC CANCER TREATED WITH STEREOTACTIC BODY RADIATION THERAPY (SBRT): ANALYSIS OF A PHASE II TRIAL</b> Pablo Munoz-Schuffenegger, Tony Panzarella, Laura Dawson, Andrea Bezjak, Patricia Lindsay, Peter Chung, Andrew Hope, Meredith Giuliani, Anne Koch, Bernard Cummings, Zahra Kassam, Mojgan Taremi, Jolie Ringash, Rebecca Wong; University of Toronto, Toronto, ON</p>   | <p><b>20</b> <b>ASSESSING HAZARD OF TOBACCO-RELATED CANCERS AMONG INDIVIDUALS WITH PSYCHIATRIC DISORDERS IN BRITISH COLUMBIA</b> Mary McLay<sup>1</sup>, Robert Olson<sup>1</sup>, Russ Callaghan<sup>2</sup>; <sup>1</sup>University of British Columbia, Vancouver, BC; <sup>2</sup>University of Northern British Columbia, Prince George, BC</p>   |
| <p><b>16</b> <b>PATIENT-REPORTED SEXUAL HEALTH AFTER DEFINITIVE CHEMORADIOTHERAPY AND MR-GUIDED BRACHYTHERAPY FOR CERVIX CANCER</b> Jennifer Croke, Rachel Gerber, Kathy Han, Jason Xie, Haiyan Jan, Akbar Beiki-Ardakani, Anthony Fyles, Michael Milosevic; Princess Margaret Cancer Centre, Toronto, ON</p>   | <p><b>21</b> <b>POPULATION-BASED STANDARDIZED SYMPTOM SCREENING: CANCER CARE ONTARIO'S EXPANDED PROSTATE CANCER INDEX COMPOSITE FOR CLINICAL PRACTICE (EPIC-CP) PROVINCIAL IMPLEMENTATION APPROACH</b> Lisa Barbera<sup>1</sup>, Farzana Haji<sup>2</sup>, Michael Brundage<sup>3</sup>, Colleen Bedford<sup>2</sup>, Doris Howell<sup>4</sup>, Brett Nicholls<sup>2</sup>; <sup>1</sup>Odette Cancer Centre, Toronto, ON; <sup>2</sup>Cancer Care Ontario, Toronto, ON; <sup>3</sup>Cancer Centre of Southeastern Ontario, Kingston, ON; <sup>4</sup>University Health Network, Toronto, ON</p> |
| <p><b>17</b> <b>TREATMENT PLANNING EVALUATION OF VOLUMETRIC MODULATED ARC THERAPY (VMAT) FOR CRANIOSPINAL IRRADIATION (CSI)</b> Salwa Fathy, Tagreed Alalawi, Nasser Al-Dhaibani; King Abdullah Medical City, Saudi Arabia, Jeddah, Saudi Arabia</p>  | <p><b>22</b> <b>RADIOTHERAPY FOR LUNG CANCER IN THE INTENSIVE CARE UNIT – A POPULATION BASED ANALYSIS</b> Alexander Louie<sup>1</sup>, Lihua Li<sup>2</sup>, Krista Bray Jenkyn<sup>1</sup>, Britney Allen<sup>2</sup>, Andrew Warner<sup>3</sup>, George Rodrigues<sup>2</sup>, David Palma<sup>2</sup>, Salimah Shariff<sup>2</sup>; <sup>1</sup>London Regional Cancer Program, London, ON; <sup>2</sup>University of Western Ontario, London, ON; <sup>3</sup>London Health Sciences Centre, London, ON</p>  |

2:45-3:45 **POSTER DISCUSSION SESSION 2** *Toronto II*

Moderators: Andrew Bayley, Jacqueline Lam

OBJECTIVES: At the end of this session, the participants will be able to discuss a variety of projects and research being conducted across the country in radiation oncology.

- |   |   |
|---|---|
| <p><b>23 PATTERNS OF RADIATION THERAPY TECHNOLOGY USE IN THE TREATMENT OF BONE METASTASES</b> Matthew Chan<sup>1</sup>, Robert Olson<sup>2</sup>, Shilo Lefresne<sup>2</sup>, Michael McKenzie<sup>2</sup>;<br/><sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>University of British Columbia, Vancouver, BC</p>  | <p><b>28 A SYSTEMATIC REVIEW OF CLINICAL OUTCOMES FOLLOWING CHEMO-RADIOTHERAPY FOR ANAL CANCER IN HIV-POSITIVE PATIENTS ON HIGHLY-ACTIVE ANTI-RETROVIRAL THERAPY (HAART)</b> Rohann Correa<sup>1</sup>, Robert Dinniwel<sup>1</sup>, Boris Virine<sup>1</sup>, Adeel Kaiser<sup>2</sup>, Mark Mishra<sup>2</sup>, Alexander Louie<sup>3</sup>; <sup>1</sup>University of Western Ontario, London, ON; <sup>2</sup>University of Maryland School of Medicine, Baltimore, MD; <sup>3</sup>London Health Sciences Centre, London, ON</p> |
| <p><b>24 MULTICENTER EVALUATION OF THE TOLERABILITY OF COMBINED TREATMENT WITH PD-1 AND CTLA-4 IMMUNE CHECKPOINT INHIBITORS AND PALLIATIVE RADIOOTHERAPY</b> Andrew Bang<sup>1</sup>, Tyler Wilhite<sup>2</sup>, Luke Pike<sup>2</sup>, Daniel Cagney<sup>2</sup>, Ayal Aizer<sup>2</sup>, Allison Taylor<sup>2</sup>, Alexander Spektor<sup>2</sup>, Monica Krishnan<sup>3</sup>, Patrick Ott<sup>2</sup>, Tracy Balboni<sup>2</sup>, Stephen Hodi<sup>2</sup>, Jonathan Schoenfeld<sup>2</sup>;<br/><sup>1</sup>University of Ottawa, Ottawa, ON; <sup>2</sup>Harvard University, Boston, MA; <sup>3</sup>Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA</p> | <p><b>29 NEOADJUVANT SBRT FOR PANCREATIC DUCTAL ADENOCARCINOMA: A SYSTEMATIC REVIEW</b> Rahul Arora<sup>1</sup>, Jan Grendar<sup>2</sup>, Petra Grendarova<sup>1</sup>, Zeljka Jutric<sup>3</sup>, Richie Sinha<sup>1</sup>; <sup>1</sup>University of Calgary, Calgary, AB; <sup>2</sup>Providence Portland Medical Center, Portland, OR; <sup>3</sup>City of Hope National Medical Center, Duarte, CA</p>   |
| <p><b>25 INFORMAL CAREGIVER QUALITY OF LIFE IN A PALLIATIVE ONCOLOGY POPULATION</b> Adele Duimering, Jill Turner, Karen Chu, Fleur Huang, Diane Severin, Sunita Ghosh, Don Yee, Ericka Wiebe, Nawaid Usmani, Zsolt Gabos, Samir Patel, Brita Danielson, John Amanie, Wilson Roa, Alysa Fairchild; Cross Cancer Institute, Edmonton, AB</p>  | <p><b>30 FACTORS AFFECTING POST-OPERATIVE CAVITY VOLUME AND SURFACE AREA DYNAMICS SPECIFIC TO BRAIN METASTASES</b> Yaser Hasan<sup>1</sup>, Luluel Khan<sup>1</sup>, Todd Mainprize<sup>1</sup>, Sunit Das<sup>1</sup>, Mark Ruschin<sup>1</sup>, Fiona Lochray<sup>2</sup>, Young Lee<sup>2</sup>, May Tsao<sup>1</sup>, Arjun Sahgal<sup>1</sup>, Hany Soliman<sup>1</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>Sunnybrook Health Sciences Centre, Toronto, ON</p>  |
| <p><b>26 DOCUMENTATION OF DRIVING RECOMMENDATIONS FOR PATIENTS RECEIVING WHOLE BRAIN RADIOOTHERAPY</b> Michael H Wang, Melissa Hwang, Sunita Ghosh, Diane Severin, Tirath Nijjar, Zsolt Gabos, Karen P Chu, Don Yee, Brock Debenham, Keith Tankel, Wilson Roa, Robert Pearcey, Kurian Joseph, Brita Danielson, Alysa Fairchild; Cross Cancer Institute, Edmonton, AB</p>  | <p><b>31 OUTCOMES OF HYPOFRACTIONATED STEREOTACTIC RADIOOTHERAPY FOR INTRACRANIAL MENINGIOMA: A SYSTEMATIC REVIEW OF THE LITERATURE</b> Timothy Nguyen<sup>1</sup>, Eric Nguyen<sup>2</sup>, Hanbo Chen<sup>1</sup>, R Gabe Boldt<sup>1</sup>, Alexander Louie<sup>1</sup>, Glenn Bauman<sup>1</sup>; <sup>1</sup>London Health Sciences Centre, London, ON; <sup>2</sup>Juravinski Cancer Centre, Hamilton, ON</p>   |
| <p><b>27 MYXOFIBROSARCOMA CHARACTERISTICS AND CLINICAL OUTCOMES AT A LARGE CANADIAN TERTIARY CANCER REFERRAL CENTRE</b> Gaurav Bhattacharya, Matthew Tsang, Horia Marginean, Samy El Sayed; The University of Ottawa, Ottawa, ON</p>  | <p><b>32 CHECKPOINT SLIPPAGE AFTER DNA DOUBLE STRAND BREAKS UNDERLIES ACTIVATION OF IR-INDUCED INFLAMMATORY SIGNALING</b> Shane Harding, Joseph Benci, Jerome Irianto, Dennis Discher, Andy Minn, Greenberg Roger; University of Pennsylvania, Philadelphia, PA</p>   |

3:45-4:00 **Break**

4:00-5:00 **FELLOW COMPETITION** *Toronto I/II*

Moderators: Michael Brundage, Gerard Morton

OBJECTIVES: At the end of this session, the participants will be able to review Canadian Radiation Oncology Fellow Research Projects.

- 33 ELEKTA FELLOWSHIP DOSIMETRIC IMPACT OF RE-PLANNING DURING A COURSE OF CURATIVE INTENT HEAD AND NECK RADIATION TREATMENT** Theodora A Koulis<sup>1</sup>, Quinn Matthews<sup>1</sup>, Nick Chng<sup>1</sup>, Bronwen Engel<sup>1</sup>, Boris Valev<sup>1</sup>, Robert Olson<sup>2</sup>; <sup>1</sup>British Columbia Cancer Agency, Prince George, BC; <sup>2</sup>University of British Columbia, Vancouver, BC
- 34 PLERIXAFOR IMPROVES PRIMARY TUMOUR RESPONSE AND REDUCES NODAL METASTASIS IN CERVICAL CANCER TREATED WITH RADIO-CHEMOTHERAPY** Magali Lecavalier-Barsoum<sup>1</sup>, Naz Chaudary<sup>2</sup>, Pratibha Tapa<sup>2</sup>, Meegan Larsen<sup>3</sup>, Melania Pintilie<sup>1</sup>, Ri Wang<sup>1</sup>, Kathy Han<sup>1</sup>, Laura Caporiccio<sup>2</sup>, Richard Hill<sup>1</sup>, Michael Milosevic<sup>1</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>Ontario Cancer Institute and Campbell Family Institute for Cancer Research, Toronto, ON; <sup>3</sup>Mbed Pathology, Toronto, ON
- 35 PATTERNS OF IPSILATERAL REGIONAL NODAL RELAPSE IN BREAST CANCER: A REVIEW OF THE RTOG BREAST CANCER ATLAS** Laura Beaton<sup>1</sup>, Luminita Nica<sup>2</sup>, Gareth Ayre<sup>2</sup>, Kenny Sek<sup>2</sup>, Maria Aparicio<sup>2</sup>, Lovedeep Gondara<sup>2</sup>, Caroline Speers<sup>2</sup>, Scott Tyldesley<sup>2</sup>, Alan Nichol<sup>2</sup>; <sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>University of British Columbia, Vancouver, BC
- 36 LONG TERM QUALITY OF LIFE AND LATE TOXICITY ASSESSMENT FOLLOWING IMAGE-GUIDED INTENSITY-MODULATED RADIATION THERAPY AND CONCURRENT CHEMOTHERAPY FOR ANAL CANCER** Ali Hosni<sup>1</sup>, Kathy Han<sup>1</sup>, Haiyan Jiang<sup>1</sup>, Jolie Ringash<sup>1</sup>, James Brierley<sup>1</sup>, Rebecca Wong<sup>1</sup>, Robert Dinniwell<sup>2</sup>, Anthony Brade<sup>3</sup>, Laura Dawson<sup>1</sup>, Bernard Cummings<sup>1</sup>, Monika Krzyzanowska<sup>1</sup>, Eric Chen<sup>1</sup>, David Hedley<sup>1</sup>, Jennifer Knox<sup>1</sup>, Alexandra Easson<sup>1</sup>, Patricia Lindsay<sup>1</sup>, Tim Craig<sup>1</sup>, John Kim<sup>1</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>University of Western Ontario, London, ON; <sup>3</sup>Credit Valley Hospital, Mississauga, ON
- 37 RISK-ADAPTED LUNG SBRT FOR CENTRAL AND ULTRA-CENTRAL TUMOURS** Alexis Lenglet, Dominique Mathieu, Marie-Pierre Campeau, Houda Bahig, Toni Vu, David Roberge, Laurent Bilodeau, Edith Filion; Université de Montréal, Montréal, QC
- 38 PARTIAL BREAST RADIOTHERAPY WITH PD-103 PERMANENT BREAST SEED IMPLANT: APPLICABILITY AND PATIENT ACCEPTANCE** Martin Korzeniowski, Laurie Pilote, Deidre Batchelar, Michelle Hiltz, Marie-Pierre Milette, Janet Yanchuk, Eleanor Garcia, Juanita Mary Crook; British Columbia Cancer Agency, Kelowna, BC

5:15-6:15 **ANNUAL GENERAL MEETING** (Members only) *Toronto I*

6:15-8:15 **POSTER VIEWING AND WELCOME RECEPTION** *Convention Level Foyer*

# FRIDAY SEPTEMBER 15, 2017

7:30-8:30 **REGISTRATION AND BREAKFAST** *Convention Level*

8:30-8:45 **WELCOME AND INTRODUCTIONS** Fabio Cury *Toronto I/II*

## 8:45-9:45 GORDON RICHARDS LECTURE

Moderator: Padraig Warde

### Advocating for Quality... Michael Brundage

OBJECTIVES: At the end of this session, the participants will be able to:

- ▮ Reflect on advocacy for quality in a number of dimensions, both past and present.
- ▮ Discuss links between the CanMEDS educational roles framework and advocacy for quality of care in radiation oncology.

## 9:45-10:45 RESIDENT COMPETITION

Moderator: Claire Snyder

OBJECTIVES: At the end of this session, the participants will be able to review Canadian Radiation Oncology Resident Research Projects.

**39 PREDICTING THE FAILURE OF RANDOMIZED CONTROLLED TRIALS IN RADIATION ONCOLOGY: WHAT CAN WE LEARN?** Timothy Nguyen<sup>1</sup>, Eric Nguyen<sup>2</sup>, Andrew Warner<sup>1</sup>, Alexander Louie<sup>1</sup>, David Palma<sup>1</sup>; <sup>1</sup>London Health Sciences Centre, London, ON; <sup>2</sup>Juravinski Cancer Centre, Hamilton, ON

**40 STEREOTACTIC ABLATIVE RADIOTHERAPY VERSUS SURGERY IN EARLY LUNG CANCER: A META-ANALYSIS OF PROPENSITY SCORE-ADJUSTED COMPARATIVE EFFECTIVENESS STUDIES** Hanbo Chen<sup>1</sup>, Joanna Laba<sup>2</sup>, R Gabriel Boldt<sup>2</sup>, Christopher Goodman<sup>1</sup>, David Palma<sup>2</sup>, Suresh Senan<sup>3</sup>, Alexander Louie<sup>2</sup>; <sup>1</sup>University of Western Ontario, London, ON; <sup>2</sup>London Health Sciences Centre, London, ON; <sup>3</sup>VU University Medical Center, Amsterdam, North Holland, Netherlands

**41 IMPROVED DISEASE CONTROL WITH ADJUVANT THERAPY FOR STAGE IA SEROUS AND CLEAR CELL UTERINE CANCER: A POOLED MULTI-INSTITUTIONAL ANALYSIS** Xuanlu Qu<sup>1</sup>, Vikram Velker<sup>2</sup>, Eric Leung<sup>3</sup>, Janice Kwon<sup>4</sup>, Mohamed Elshaikh<sup>5</sup>, Iwa Kong<sup>6</sup>, Natalie Logie<sup>7</sup>, Lucas Castro Mendez<sup>3</sup>, Louis van der Putten<sup>4</sup>, Elysia Donovan<sup>6</sup>, Adnan Munkarah<sup>8</sup>, Ericka Wiebe<sup>7</sup>, Alexander Louie<sup>9</sup>, David D'Souza<sup>4</sup>; <sup>1</sup>Queen's University, Kingston, ON; <sup>2</sup>University of Western Ontario, London, ON; <sup>3</sup>University of Toronto, Toronto, ON; <sup>4</sup>University of British Columbia, Vancouver, BC; <sup>5</sup>Henry Ford Hospital, Detroit, MI; <sup>6</sup>McMaster University, Hamilton, ON; <sup>7</sup>University of Alberta, Edmonton, AB; <sup>8</sup>Gynecology/Oncology, Detroit, MI; <sup>9</sup>London Health Sciences Centre, London, ON

**42 CBCT DERIVED RADIOSENSITIVITY MARKER ASSOCIATED WITH RADIATION PNEUMONITIS** Pencilla Lang<sup>1</sup>, Douglas Moseley<sup>2</sup>, Uffe Bernchou<sup>3</sup>, Carsten Brink<sup>3</sup>, Andrew Hope<sup>1</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>3</sup>Odense University Hospital, Odense, Denmark

**43 STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOMETASTATIC AND OLIGOPROGRESSIVE DISEASE** Catherine Pembroke, Neil Kopek; McGill University, Montreal, QC

**44 VALIDATION OF THE TEACHH SCORE FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTASIS TO THE SPINE** Maryam Dosani<sup>1</sup>, Sarah Hamilton<sup>1</sup>, Tim Kong<sup>2</sup>, Sarah Lucas<sup>1</sup>, Jordan Wong<sup>1</sup>, Mitchell Liu<sup>1</sup>, Scott Tyldesley<sup>1</sup>; <sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>University of British Columbia, Vancouver, BC

10:45-11:30 **Break/Exhibitor Showcase**



11:30-12:30 **ORAL SESSION 3 – LUNG CANCER** *Toronto I*

Moderators: Daniel Glick, Ross Halperin

OBJECTIVES: At the end of this session, the participants will be able to:

- Understand modern approaches in the treatment of lung cancer using SBRT.
- Discuss risk stratification, quality of life, and current practice of treatment of lung cancer.

**45 METABOLIC TUMOUR VOLUME IS PROGNOSTIC OF OUTCOMES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH STEREOTACTIC ABLATIVE RADIOTHERAPY**

Maryam Dosani<sup>1</sup>, Rob Olson<sup>1</sup>, Ruobing Yang<sup>1</sup>, Don Wilson<sup>1</sup>, Mitchell Liu<sup>1</sup>, Charlotte J Yong-Hing<sup>1</sup>, Jeremy Hamm<sup>1</sup>, Chad R Lund<sup>2</sup>, Devin Schellenberg<sup>2</sup>; <sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>British Columbia Cancer Agency, Surrey, BC

**46 CENTRAL3D: A CLINICIAN TOOL FOR ROBUST CHARACTERIZATION OF CENTRALLY LOCATED NON-SMALL CELL LUNG CANCER**

Dominique Mathieu, Vincent Cousineau Daoust, Laurent Bilodeau, Stéphane Bedwani, Édith Filion, Alexis Lenglet, Houda Bahig, David Roberge, Marie-Pierre Campeau; Université de Montréal, Montréal, QC; Centre hospitalier de l'Université de Montréal, Montréal, QC

**47 FUNCTIONAL LUNG AVOIDANCE FOR INDIVIDUALIZED RADIOTHERAPY (FLAIR): RESULTS OF A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL**

Brian Yaremko<sup>1</sup>, Douglas Hoover<sup>1</sup>, Dante Capaldi<sup>1</sup>, Khadija Sheikh<sup>1</sup>, A Rashid Dar<sup>1</sup>, Edward Yu<sup>1</sup>, Alexander Louie<sup>2</sup>, George Rodrigues<sup>1</sup>, Stewart Gaede<sup>1</sup>, Jeff Chen<sup>1</sup>, Abigail Erickson<sup>2</sup>, Andrew Warner<sup>2</sup>, Brian Dingle<sup>1</sup>, Mark Landis<sup>1</sup>, Mark Vincent<sup>1</sup>, Michael Sanatani<sup>1</sup>, Jawaid Younus<sup>1</sup>, M Sara Kuruvilla<sup>1</sup>, David Palma<sup>1</sup>, Grace Parraga<sup>1</sup>; <sup>1</sup>University of Western Ontario, London, ON; <sup>2</sup>London Health Sciences Centre, London, ON

**48 IS STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) SAFE FOR THE TREATMENT OF ULTRA-CENTRAL LUNG TUMOURS? A SYSTEMATIC REVIEW**

Joanna Laba<sup>1</sup>, Hanbo Chen<sup>1</sup>, R Gabriel Boldt<sup>2</sup>, David Palma<sup>1</sup>, Alexander Louie<sup>2</sup>; <sup>1</sup>University of Western Ontario, London, ON; <sup>2</sup>London Health Sciences Centre, London, ON

**49 CARO ELEKTA CONDITIONAL SURVIVAL PROBABILITIES FOLLOWING SABR IN EARLY-STAGE NON-SMALL CELL LUNG CANCER**

Alexander Louie<sup>1</sup>, Mark Mishra<sup>2</sup>, Frank Lagerwaard<sup>3</sup>, Cornelis Haasbeek<sup>3</sup>, Ben Slotman<sup>3</sup>, Suresh Senan<sup>3</sup>; <sup>1</sup>London Regional Cancer Program, London, ON; <sup>2</sup>University of Maryland School of Medicine, Baltimore, MD; <sup>3</sup>VU University Medical Center, Amsterdam, Netherlands

**50 DEFINING THE NEED FOR PALLIATIVE LUNG CANCER RADIOTHERAPY IN THE GENERAL POPULATION: A CRITERION-BASED BENCHMARKING APPROACH**

Chunzi Jenny Jin, Weidong Kong, William Mackillop; Queen's University, Kingston, ON

11:30-12:30 **ORAL SESSION 4 – GENITOURINARY CANCER, RADIATION TREATMENT DELIVERY** *Toronto II*

Moderators: Juanita Crook, Guila Delouya

OBJECTIVES: At the end of this session, the participants will be able to:

- Understand predicting factors, toxicities and outcomes of prostate cancer treatment with radiation therapy.
- Understand important concepts in treatment planning and delivery of modern radiation therapy.

**51 MRI VALIDATION OF POST – PROSTATECTOMY RADIOTHERAPY CONTOURING GUIDELINES**

Mo Manji, Juanita Crook, Leigh Bartha, Rasika Rajapakshe; British Columbia Cancer Agency, Kelowna, BC

**52 RADIATION THERAPY FOLLOWING ACTIVE SURVEILLANCE FOR LOW – AND INTERMEDIATE – RISK LOCALIZED PROSTATE CANCER**

Ali Hosni, Ardalan Ahmad, Melvin Chua, Jure Murgic, Hamid Raziee, Fabio Moraes, Narhari Timilshina, Andrew Bayley, Peter Chung, Robert Bristow, Antonio Finelli, Alejandro Berlin; Princess Margaret Cancer Centre, Toronto, ON

**53 RANDOMIZED STUDY OF QUALITY OF LIFE IN PATIENTS WITH HIGH-RISK PROSTATE CANCER UNDERGOING RADIOTHERAPY: ROLE OF PELVIC NODAL IMRT**

Julie Arseneault, Sameer Parpia, Himanshu Lukka, Thomas B Corbett, Maltibehn Patel, Theodoros Tsakiridis, Ian Dayes; McMaster University, Hamilton, ON

**54 A SET OF QUALITY ASSURANCE TESTS FOR 3D PRINTED BOLUS USED IN RADIOTHERAPY**

Philip McGeachy<sup>1</sup>, David Sasaki<sup>2</sup>, Chad Harris<sup>1</sup>, Ankur Sharma<sup>1</sup>, Arbind Dubey<sup>2</sup>; <sup>1</sup>CancerCare Manitoba, Winnipeg, MB; <sup>2</sup>University of Manitoba, Winnipeg, MB



- 55 FACTORS ASSOCIATED WITH IN-FIELD RECURRENCE IN PATIENTS TREATED WITH LIVER SBRT** Emily Hubley<sup>1</sup>, Sarah Quirk<sup>1</sup>, Richie Sinha<sup>1</sup>, Shaun Loewen<sup>1</sup>, Petra Grendarova<sup>2</sup>;

<sup>1</sup>University of Calgary, Calgary, AB; <sup>2</sup>Tom Baker Cancer Centre, University of Calgary, Calgary, AB

- 56 PROGRESSIVE HYPO FRACTIONATED IGRT REGIMENS: TOXICITY, ACCEPTABILITY AND EFFICIENCY OF DELIVERY COMPARED TO A STANDARD FRACTIONATION REGIMEN, BOTH WITH HDR BRACHYTHERAPY BOOST** André-Guy Martin<sup>1</sup>, Khaly Mbodji<sup>1</sup>, William Foster<sup>1</sup>, Éric Vigneault<sup>1</sup>, Philippe Després<sup>2</sup>, Marie-Claude Lavallée<sup>1</sup>, Frederic Lacroix<sup>1</sup>, Nadia Octave<sup>1</sup>;

<sup>1</sup>Centre Hospitalier Universitaire de Québec – L'Hôtel-Dieu de Québec, Québec, QC; <sup>2</sup>Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec QC

12:30-2:30 **Lunch Break**

**COMMITTEE MEETINGS** Please refer to the Committee Meetings Schedule for exact times

2:30-3:30 **CANADIAN BRACHYTHERAPY GROUP ORAL SESSION** Toronto I

Moderator: Marc Gaudet, Gerard Morton

OBJECTIVES: At the end of this session, the participants will be able to:

- ▮ Recognize the most recent advances on brachytherapy research for prostate and cervical cancer.
- ▮ Discuss the results of a Phase III trial on brachytherapy for lung cancer.

- 57 TOXICITY AND HEALTH-RELATED QUALITY OF LIFE RESULTS OF 2-FRACTION HDR BRACHYTHERAPY AS MONOTHERAPY FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER** Marc Gaudet<sup>1</sup>, Mathieu Pharand-Charbonneau<sup>2</sup>, Debbie Wright<sup>2</sup>, Marie-Pierre Desrosiers<sup>2</sup>, Alain Haddad<sup>3</sup>;

<sup>1</sup>The Ottawa Hospital, Ottawa, ON; <sup>2</sup>CISSS de l'Outaouais, Gatineau, QC; <sup>3</sup>University of Ottawa, Ottawa, ON

- 58 US-PLANNED HDR PROSTATE BRACHYTHERAPY BOOST: ACUTE AND LATE TOXICITY** Laurie Pilote<sup>1</sup>, Juanita Crook<sup>1</sup>, Miren Gaztañaga<sup>2</sup>, Ana Ots<sup>3</sup>, Jasbir Jaswal<sup>4</sup>, Jim Rose<sup>5</sup>, Audrey Tetreault Laflamme<sup>6</sup>, Cynthia Araujo<sup>1</sup>, Batchelar Deidre<sup>1</sup>, Marie-Pierre Millette<sup>1</sup>, Schmid Matthew<sup>1</sup>, Martin Korzeniowski<sup>1</sup>, Francois Bachand<sup>1</sup>;

<sup>1</sup>British Columbia Cancer Agency, Kelowna, BC; <sup>2</sup>Departamento Oncología Radioterapia, Madrid, Spain; <sup>3</sup>United Lincolnshire Hospitals, Lincoln, United Kingdom; <sup>4</sup>British Columbia Cancer Agency, Fraser Valley, BC; <sup>5</sup>British Columbia Cancer Agency, Abbotsford, BC; <sup>6</sup>Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC

- 59 ELECTROMAGNETIC RECONSTRUCTION OF CATHETER PATHS IN MULTI-CATHETER INTERSTITIAL BRACHYTHERAPY: A PHANTOM MODEL** Harry C Brastianos<sup>1</sup>, Thomas Vaughan<sup>1</sup>, Andras Lasso<sup>1</sup>, Tamas Ungi<sup>1</sup>, Mary Westerland<sup>2</sup>, James Gooding<sup>1</sup>, Gabor Fichtinger<sup>1</sup>, Conrad Falkson<sup>1</sup>;

<sup>1</sup>Queen's University, Kingston, ON; <sup>2</sup>Kingston General Hospital, Kingston, ON

- 60 A PHASE III, MULTI-CENTRE, RANDOMIZED TRIAL TO EVALUATE THE SYMPTOMATIC AND QUALITY OF LIFE IMPROVEMENTS IN LUNG CANCER PATIENTS RECEIVING EXTERNAL BEAM RADIATION WITH OR WITHOUT HIGH DOSE RATE INTRALUMINAL BRACHYTHERAPY** Ranjan Sur<sup>1</sup>, Conrad Falkson<sup>2</sup>, Ming Pan<sup>3</sup>, Greg Pond<sup>1</sup>, Jim Wright<sup>4</sup>, Andrea Beznak<sup>5</sup>, Anne Dagnault<sup>6</sup>, Robert Hunter<sup>4</sup>, Edward Yu<sup>5</sup>,

Maha Almahmudi<sup>6</sup>, Sundeep Shahi<sup>7</sup>, Serhij Puksa<sup>1</sup>, Daren Gopaul<sup>7</sup>, Theodorus Tsakiridis<sup>1</sup>, Anand Swaminath<sup>1</sup>, Peter Ellis<sup>1</sup>, Kathryn Kline<sup>1</sup>, Catherine Bucci<sup>4</sup>, Sheikh Nisar Ahmed<sup>6</sup>, Timothy Whelan<sup>1</sup>;

<sup>1</sup>McMaster University, Hamilton, ON; <sup>2</sup>Queen's University, Kingston, ON; <sup>3</sup>Windsor Regional Cancer Centre, Windsor, ON; <sup>4</sup>Juravinski Cancer Centre, Hamilton, ON; <sup>5</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>6</sup>Hôtel-Dieu de Québec, CHUQ, Quebec City, QC; <sup>7</sup>University of Western Ontario, London Regional Cancer Centre, London, ON; <sup>8</sup>British Columbia Cancer Agency, Abbotsford, BC; <sup>9</sup>Grand River Regional Cancer Centre, Kitchener, ON

- 61 THE CURRENT LANDSCAPE OF QUALITY ASSURANCE PRACTICES FOR CERVIX BRACHYTHERAPY IN CANADA** Jocelyn Moore<sup>1</sup>, Peter Lim<sup>1</sup>, Jennifer Croke<sup>2</sup>, Corinne Doll<sup>3</sup>, Fleur Huang<sup>4</sup>, Teri Stuckless<sup>5</sup>, Maroie Barkati<sup>6</sup>, Christina Parsons<sup>1</sup>;

<sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>3</sup>Tom Baker Cancer Centre, Calgary, AB; <sup>4</sup>Cross Cancer Institute, Edmonton, AB; <sup>5</sup>Dr H Bliss Murphy Cancer Centre, St John's, NL; <sup>6</sup>Centre hospitalier de l'Université de Montréal, Montreal, QC

- 62 A COST-UTILITY ANALYSIS COMPARING MR-GUIDED BRACHYTHERAPY TO 2D BRACHYTHERAPY FOR MANAGEMENT OF LOCALLY ADVANCED CERVICAL CANCER IN ONTARIO, CANADA** Julia Skliarenko<sup>1</sup>, Johnna Perdrizet<sup>2</sup>, Michelle Ang<sup>3</sup>, Lisa Barbera<sup>4</sup>, Eric Gutierrez<sup>3</sup>, Ananth Ravi<sup>4</sup>, Kari Tanderup<sup>5</sup>, Padraig Warde<sup>3</sup>, David D'Souza<sup>6</sup>, Kelvin Chan<sup>7</sup>, Wanrudee Isaranuwachai<sup>2</sup>, Michael Milosevic<sup>4</sup>;

<sup>1</sup>Simcoe Muskoka Regional Cancer Program, Barrie, ON; <sup>2</sup>St Michael's Hospital, Toronto, ON; <sup>3</sup>CancerCare Ontario, Toronto, ON; <sup>4</sup>University of Toronto, Toronto, ON; <sup>5</sup>Aarhus University Hospital, Aarhus, Denmark; <sup>6</sup>London Health Sciences Centre, London, ON; <sup>7</sup>Odette Cancer Centre, Toronto, ON

3:30-4:30 **ORAL SESSION 5 – RADIATION TREATMENT, RADIOSURGERY** *Toronto I*

Moderator: Francois Bachand, David Palma

OBJECTIVES: At the end of this session, the participants will be able to:

- | Discuss important factors related to quality of treatment planning and delivery.
- | Understand the most recent advances in radiosurgery and its impact on treatment outcomes.

**63 SURVIVAL IMPACT OF CARDIAC DOSE IN LUNG STEREOTACTIC BODY RADIOTHERAPY** Olive Wong<sup>1</sup>, Vivian Yau<sup>1</sup>, Julie Kang<sup>1</sup>, Daniel Glick<sup>2</sup>, Patricia Lindsay<sup>3</sup>, Lisa Le<sup>1</sup>, Alexander Sun<sup>3</sup>, Andrea Bezjak<sup>3</sup>, John Cho<sup>3</sup>, Andrew Hope<sup>3</sup>, Meredith Giuliani<sup>3</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>3</sup>University of Toronto, Toronto, ON

**64 ASSESSMENT OF DOSIMETRIC PREDICTORS AND IMPACT OF WHOLE-BRAIN RADIOTHERAPY ON THE INCIDENCE OF RADIONECROSIS AFTER STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASIS** Hamid Raziee<sup>1</sup>, Fabio Y Moraes<sup>2</sup>, Young-Bin Cho<sup>2</sup>, Manjula Magnati<sup>2</sup>, David Shultz<sup>2</sup>, Barbara-Ann Millar<sup>2</sup>, Normand Laperriere<sup>1</sup>, Caroline Chung<sup>3</sup>, Alejandro Berlin<sup>2</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>3</sup>MD Anderson Cancer Center, University of Texas, Houston, TX

**65 EXTREME HYPOFRACTIONATION FOR HIGH RISK PROSTATE CANCER: DOSIMETRIC CORRELATIONS WITH RECTAL BLEEDING** Glenn Bauman<sup>1</sup>, Jeff Chen<sup>2</sup>, George Rodrigues<sup>2</sup>, Kristina Commisso<sup>3</sup>, Alexandre Mamedov<sup>4</sup>, Hima Musunuru<sup>5</sup>, Melanie Davidson<sup>4</sup>, Tristan Mills<sup>1</sup>, Andrew Warner<sup>2</sup>, Andrew Loblaw<sup>4</sup>; <sup>1</sup>London Regional Cancer Program, London, ON; <sup>2</sup>University of Western Ontario, London, ON; <sup>3</sup>Sunnybrook Odette Cancer Centre, Toronto, ON; <sup>4</sup>University of Toronto, Toronto, ON; <sup>5</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI

**66 OUTCOMES FOR IMAGE-GUIDED FRAMELESS LINEAR ACCELERATOR-BASED HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY IN FIVE DAILY FRACTIONS TO THE SURGICAL CAVITY AFTER RESECTION OF BRAIN METASTASES** Hany Soliman<sup>1</sup>, Sten Myrehaug<sup>1</sup>, May Tsao<sup>1</sup>, Chia-Lin Tseng<sup>1</sup>, Ahmed Hashmi<sup>2</sup>, Mark Ruschin<sup>1</sup>, Young Lee<sup>1</sup>, Arjun Sahgal; <sup>1</sup>Odette Cancer Centre, University of Toronto, Toronto, ON; <sup>2</sup>Clatterbridge Cancer Centre, Merseyside, UK

**67 POST-SURGICAL CLIPS AS FIDUCIALS FOR TREATMENT OF STEREOTACTIC BODY RADIOTHERAPY OF THE LIVER** Muhammad Faisal Jamaluddin, Kurian Joseph, Diane Severin, Joel St Aubin, Adele Duimerring, Shannah Murland, Zsolt Gabos, Keith Tankel University of Alberta, Edmonton, AB

**68 ESOPHAGEAL TOXICITY IN THORACIC STEREOTACTIC RADIOTHERAPY** Vivian Yau<sup>1</sup>, Patricia Lindsay<sup>1</sup>, Andrew Hope<sup>1</sup>, Lisa Le<sup>1</sup>, Daniel Glick<sup>2</sup>, Anthea Lau<sup>1</sup>, John Cho<sup>2</sup>, Andrea Bezjak<sup>1</sup>, Alex Sun<sup>2</sup>, Meredith Giuliani<sup>2</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>British Columbia Cancer Agency, Victoria, BC

3:30-4:30 **ORAL SESSION 6 – GYNECOLOGIC CANCER** *Toronto II*

Moderators: Joanne Alfieri, Jennifer Croke

OBJECTIVES: At the end of this session, the participants will be able to:

- | Discuss treatment planning, quality of life, and outcomes of radiotherapy for gynecological tumours.
- | Review possible factors that can be associated with treatment outcomes in the management of gynecologic malignancies.

**69 PRECLINICAL ASSESSMENT OF ACUTE AND LATE GASTROINTESTINAL TOXICITY WITH THE ADDITION OF PLERIXAFOR TO RADIO – CHEMOTHERAPY FOR CERVICAL CANCER** Naz Chaudary<sup>1</sup>, Magali Lecavalier-Barsoum<sup>1</sup>, Pratibha Thapa<sup>1</sup>, Meegan Larsen<sup>2</sup>, Melania Pintilie<sup>1</sup>, Kathy Han<sup>1</sup>, Richard Hill<sup>1</sup>, Michael Milosevic<sup>1</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>Mbed Pathology, Toronto, ON

**70 VALIDATION OF PATIENT REPORTED OUTCOME MEASURES IN PATIENTS RECEIVING HIGH DOSE PELVIC RADIATION THERAPY FOR GYNECOLOGIC MALIGNANCIES**; Matthew Chan<sup>1</sup>, Vincent Lapointe<sup>1</sup>, Robert Olson<sup>2</sup>, Caroline Holloway<sup>3</sup>, Francois Bachand<sup>4</sup>, Peter Lim<sup>1</sup>, Christina Parsons<sup>1</sup>; <sup>1</sup>British Columbia

Cancer Agency, Vancouver, BC; <sup>2</sup>University of British Columbia, Vancouver, BC; <sup>3</sup>British Columbia Cancer Agency, Vancouver Island, BC; <sup>4</sup>British Columbia Cancer Agency, Kelowna, BC

**71 ADJUVANT CHEMO-RADIATION FOR CLEAR CELL CARCINOMA OF THE OVARY: A POPULATION BASED STUDY OF PELVIC VERSUS WHOLE ABDOMINAL RADIATION THERAPY** Soumyajit Roy<sup>1</sup>, Anna Tinker<sup>2</sup>, Paul Hoskins<sup>2</sup>, Francois Bachand<sup>3</sup>, Caroline Holloway<sup>4</sup>, Christina Parsons<sup>2</sup>, Peter Lim<sup>2</sup>, Gaurav Bahl<sup>1</sup>; <sup>1</sup>British Columbia Cancer Agency, Abbotsford, BC; <sup>2</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>3</sup>British Columbia Cancer Agency, Kelowna, BC; <sup>4</sup>British Columbia Cancer Agency, Vancouver Island, BC

**72 CONTOURING AND TARGET VARIABILITY IN VAGINAL TUMOURS TREATED WITH MR-BASED INTERSTITIAL BRACHYTHERAPY: A MULTI-CENTRE CANADIAN CONTOURING STUDY**

Eric Leung<sup>1</sup>, David D'Souza<sup>2</sup>, Joanne Alfieri<sup>3</sup>, Robyn Banerjee<sup>4</sup>, Francois Bachand<sup>5</sup>, Lisa Barbera<sup>6</sup>, Maroie Barkati<sup>7</sup>, Toni Barnes<sup>6</sup>, David Bowes<sup>8</sup>, Israel Fortin<sup>7</sup>, William Foster<sup>9</sup>, Kathy Han<sup>10</sup>, Fleur Huang<sup>11</sup>, Nikhilesh Patil<sup>8</sup>, Vikram Velker<sup>2</sup>, Eric Vigneault<sup>9</sup>, Ericka Wiebe<sup>11</sup>, Matt Wronski<sup>6</sup>, Ananth Ravi<sup>6</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>London Health Sciences Centre, London, ON; <sup>3</sup>McGill University Health Centre, Montreal, QC; <sup>4</sup>Tom Baker Cancer Centre, Calgary, AB; <sup>5</sup>British Columbia Cancer Agency, Kelowna, BC; <sup>6</sup>Sunnybrook Health Sciences Centre, Toronto, ON; <sup>7</sup>CHUM – Hôpital Notre-Dame, Montreal, QC; <sup>8</sup>Nova Scotia Cancer Centre, Halifax, NS; <sup>9</sup>Centre Hospitalier Universitaire de Quebec, Quebec, QC; <sup>10</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>11</sup>Cross Cancer Institute, Edmonton, AB

**73 PIK3CA MUTATIONAL STATUS AND POST CHEMORADIOOTHERAPY 18F-FDG-PET IMAGING RESPONSE IN PATIENTS WITH CERVICAL CANCER**

Kevin Martell, John McIntyre, Elizabeth Kornaga, Angela Chan, Tien Phan, Martin Koebel, Prafull Ghatage, Susan Lees-Miller, Corinne Doll; University of Calgary, Calgary, AB

**74 3D IMAGE GUIDED INTERSTITIAL BRACHYTHERAPY FOR PRIMARY VAGINAL CANCER**

Chris Goodman<sup>1</sup>, Vikram Velker<sup>1</sup>, Eric Leung<sup>2</sup>, Alexander V Louie<sup>1</sup>, George Hajdok<sup>1</sup>, Nikhilesh Patil<sup>3</sup>, Ericka Wiebe<sup>4</sup>, David D'Souza<sup>1</sup>; <sup>1</sup>University of Western Ontario, London, ON; <sup>2</sup>University of Toronto, Toronto, ON; <sup>3</sup>Dalhousie University, Halifax, NS; <sup>4</sup>University of Alberta, Edmonton, AB

4:30-6:00 **WORKSHOPS**

**WORKSHOP 1** *Toronto II*

**QUALITY ASSURANCE IN PALLIATIVE RADIATION THERAPY AND SYMPTOM CONTROL** Kristopher Dennis

OBJECTIVES: At the end of this workshop, the participants will be able to:

- | Appreciate the need for, and the complexity of providing quality assurance for non-stereotactic palliative radiation therapy and symptom control.
- | Understand the current state of peer review practices in Canada for non-stereotactic palliative radiation therapy.
- | Be aware of best practice resources for non-stereotactic palliative radiation therapy and symptom control.
- | Be aware of potential future metrics for measuring quality within this environment.

**WORKSHOP 2** *Jackson*

**WHY WOULDN'T YA? A WIN/WIN STRATEGY USING ADVANCED PRACTICE RADIATION THERAPISTS**

Nicole Harnett, Robert Dinniwell, Padraig Warde, Grace Lee

OBJECTIVES: At the end of this workshop, the participants will be able to:

- | Describe what an Advanced Practice Radiation Therapist (CSRT) is and provide examples of the work that CSRTs are currently doing in Ontario.
- | Discuss the pressures currently facing the radiation medicine domain and how CSRTs could play a role in alleviating these pressures.
- | Identify opportunities to permanently integrate CSRTs into the radiation medicine team.

**WORKSHOP 3** *Tom Thomson*

**PAN-CANADIAN PRO COLLECTION: WORKING TOGETHER TO ADVANCE PATIENT CARE**

Robert Olson, Lisa Barbera, Amanda Caissie, Michael Milosevic, Erika Brown

OBJECTIVES: At the end of this workshop, the participants will be able to:

- | Learn about what patient reported outcomes are and how they can help improve clinical care, symptom control and patient outcomes.
- | Learn about the British Columbia Cancer Agency's Prospective Outcomes and Support Initiative (POSI) and Cancer Care Ontario's Patient Reported Outcome Program.
- | Discuss how standardizing PRO collection models in specific disease sites can advance quality of care in patient populations across the country and how the Canadian Partnership for Quality Radiotherapy is helping facilitate and drive pan – Canadian alignment.
- | Learn ways to increase the utility of PRO within practice.

7:30

**DINNER AND AWARDS CEREMONY**  
**THE RED CARPET AFFAIR**

*Grand Banking Hall, One King West*

# SATURDAY SEPTEMBER 16, 2017

7:15-8:15 **PAMELA CATTON MEMORIAL FUN RUN/WALK**

*Meet at the University Avenue Lobby Door at 7:00am.*

8:30-9:30 **COMMITTEE MEETINGS** *Please refer to the Committee Meetings Schedule for exact times*

8:30-9:30 **REGISTRATION AND BREAKFAST**

9:30-10:30 **Jean Roy Lecture** *Toronto I*

Moderator: Eric Vigneault

## Brachytherapy Education in an Era of High Technology

Gerard Morton

OBJECTIVES: At the end of this session, the participants will be able to:

- ▮ Identify limitations of current training in brachytherapy.
- ▮ Describe how Royal College Area of Focused Competency (AFC) Diploma programs might address these needs.

10:30-11:30 **ORAL SESSION 7 – HEAD AND NECK CANCER** *Toronto I*

Moderators: Daniel Glick, David Petrik

OBJECTIVES: At the end of this session, the participants will be able to:

- ▮ Describe important factors associated with the improvement of treatment outcomes for patients with head and neck malignancies.
- ▮ Review possible methods to decrease toxicity during radiation therapy for head and neck cancers.

**75 STEREOTACTIC BODY RADIOTHERAPY (SBRT) PROVIDES AN EXCELLENT LOCAL CONTROL WITH ACCEPTABLE TOXICITIES IN MEDICALLY UNFIT HEAD AND NECK CANCER PATIENTS**

Hossam AL-Assaf, Ian Poon, Justin Lee, Irene Karam, Kevin Higgins, Danny Enepekides; University of Toronto, Toronto, ON

O'Sullivan<sup>1</sup>, Scott Bratman<sup>1</sup>, Fei-Fei Liu<sup>1</sup>;

<sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>University Health Network, Toronto, ON; <sup>3</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>4</sup>Dana-Farber Cancer Institute, Boston, MA

**76 EARLY (90-DAY) MORTALITY AFTER RADICAL RADIOTHERAPY FOR HEAD & NECK SQUAMOUS CELL CARCINOMA: A POPULATION-BASED ANALYSIS**

Sarah Hamilton<sup>1</sup>, Eric Tran<sup>1</sup>, Eric Berthelet<sup>1</sup>, Jonn Wu<sup>1</sup>, Robert Olson<sup>2</sup>; <sup>1</sup>British Columbia Cancer Agency, Vancouver, BC; <sup>2</sup>University of British Columbia, Vancouver, BC

**79 EVALUATION OF DIFFERENCES BETWEEN ESTIMATED DELIVERED DOSE AND PLANNED DOSE IN NASOPHARYNX PATIENTS USING DEFORMABLE IMAGE REGISTRATION AND DOSE ACCUMULATION**

Olive Wong<sup>1</sup>, Andrea McNiven<sup>2</sup>, Biu Chan<sup>1</sup>, Joanne Moseley<sup>1</sup>, Jenny Lee<sup>1</sup>, Lisa Le<sup>1</sup>, Cijian Ren<sup>1</sup>, John Waldron<sup>2</sup>, Jean-Pierre Bissonnette<sup>2</sup>, Meredith Giuliani<sup>2</sup>, Beibei Zhang<sup>2</sup>; <sup>1</sup>Princess Margaret Cancer Centre, Toronto, ON; <sup>2</sup>University of Toronto, Toronto, ON

**77 DISTANT METASTASES RISK-GROUP DEFINITION OF ORAL SQUAMOUS CELL CARCINOMA PATIENTS TREATED WITH POSTOPERATIVE INTENSITY MODULATED RADIOTHERAPY**

Ali Hosni, Kevin Chiu, Shao Hui Huang, Wei Xu, Jie Su, Li Tong, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, John Kim, Jolie Ringash, John Waldron, John de Almeida, Douglas Chepeha, David Goldstein, Brian O'Sullivan, Andrew Hope; Princess Margaret Cancer Centre, Toronto, ON

**80 TREATMENT OUTCOMES IN OROPHARYNX CANCER PATIENTS WHO RECEIVED LESS THAN THE PLANNED CURATIVE RADIOTHERAPY DOSE**

Fatimah Alfaraj<sup>1</sup>, Shao Hui Huang<sup>1</sup>, Brian O'Sullivan<sup>1</sup>, Jie Su<sup>1</sup>, Andrew Bayley<sup>1</sup>, Scott Bratman<sup>1</sup>, John Cho<sup>1</sup>, Meredith Giuliani<sup>1</sup>, John Kim<sup>1</sup>, Jolie Ringash<sup>1</sup>, John Waldron<sup>1</sup>, Aaron Hansen<sup>1</sup>, Ana Spreafico<sup>1</sup>, John de Almeida<sup>1</sup>, Bayardo Perez-Ordenez<sup>2</sup>, Ilan Weinreb<sup>2</sup>, Li Tong<sup>2</sup>, Wei Xu<sup>3</sup>, Andrew Hope<sup>3</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>University Health Network, Toronto, ON; <sup>3</sup>Princess Margaret Cancer Centre, Toronto, ON

**78 A RADIOMIC PROGNOSTIC INDEX REFINES RISK MODELS FOR DISTANT METASTASIS IN HPV-RELATED OROPHARYNGEAL CANCER**

Jennifer Kwan<sup>1</sup>, Jie Su<sup>2</sup>, Shao Hui Huang<sup>1</sup>, Wei Xu<sup>2</sup>, Kenneth Yip<sup>3</sup>, Meredith Giuliani<sup>1</sup>, Andrew Bayley<sup>1</sup>, John Kim<sup>1</sup>, Andrew Hope<sup>3</sup>, Jolie Ringash<sup>1</sup>, John Cho<sup>1</sup>, Andrea McNiven<sup>1</sup>, Aaron Hansen<sup>1</sup>, David Goldstein<sup>1</sup>, Hugo Aerts<sup>4</sup>, John Waldron<sup>1</sup>, Benjamin Haibe-Kains<sup>1</sup>, Brian

10:30-11:30 **ORAL SESSION 8 – CNS, EXPERIMENTAL THERAPEUTICS** *Toronto II*

Moderators: Valerie Panet-Raymond, John Thoms

OBJECTIVES: At the end of this session, the participants will be able to:

- ▮ Review important aspects associated with treatment delivery and outcomes of patients undergoing treatment for CNS tumours.
- ▮ Describe relevant biomarkers for effectiveness and toxicity of cancer therapy.

**81 CLINICAL OUTCOMES OF 24 GY IN 2 DAILY FRACTIONS FOR PATIENTS WITH DE NOVO SPINAL METASTASES TREATED WITH SPINE STEREOTACTIC BODY RADIOTHERAPY (SBRT)**

Chia-Lin Tseng, Mikki Campbell, Hany Soliman, Sten Myrehaug, Mark Ruschin, Young Lee, Eshetu Atenafu, Arjun Sahgal; University of Toronto, Toronto, ON

**82 PROGNOSTIC FACTORS IN ATYPICAL MENINGIOMA**

Luis Souhami, Shakir Shakir, Kevin Petrecca, Jose Joao Mansure, George Shenouda, Valerie Panet-Raymond, Bassam Abdulkarim, Marie Christine Guiot; McGill University Health Centre, Montréal, QC

**83 CANADIAN PATTERNS OF PRACTICE FOR INTRACRANIAL GERM CELL TUMOURS IN ADOLESCENTS AND YOUNG ADULTS**

Andrea Lo<sup>1</sup>, Normand Laperriere<sup>1</sup>, David Hodgson<sup>1</sup>, Eric Bouffet<sup>1</sup>, James Nicholson<sup>2</sup>, Michael McKenzie<sup>3</sup>, Juliette Hukin<sup>3</sup>, Karen Goddard<sup>3</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>Cambridge University, Cambridge, United Kingdom; <sup>3</sup>University of British Columbia, Vancouver, BC

**84 IMPROVING RADIATION RESPONSE IN HORMONE SENSITIVE AND RESISTANT PROSTATE CANCER WITH COMBINED METFORMIN AND SALICYLATE TREATMENT – MODULATION OF THE AMPK PATHWAY AND LIPOGENESIS**

Lindsay A Broadfield<sup>1</sup>, Katarina Marcinko<sup>1</sup>, Carrie Gerdes<sup>2</sup>, Danitra Maharaj<sup>2</sup>, Thomas Farrell<sup>2</sup>, Gregory R Steinberg<sup>1</sup>, Theodoros Tsakiridis<sup>2</sup>; <sup>1</sup>McMaster University, Hamilton, ON; <sup>2</sup>Juravinski Cancer Centre, Hamilton, ON

**85 PLASMA HPV DNA AS A BIOMARKER OF RESPONSE IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER TREATED WITH DEFINITIVE CHEMORADIATION**

Eric Leung, Scott Bratman, Kathy Han; University of Toronto, Toronto, ON

**86 DATA-MINING TCGA PATHOLOGY REPORTS FOR PAN-CANCER GENOTYPE-HISTOLOGIC PHENOTYPE RELATIONSHIPS THAT INFORM PROGNOSIS**

Jonathan So<sup>1</sup>, Stanley Liu<sup>2</sup>; <sup>1</sup>University of Toronto, Toronto, ON; <sup>2</sup>Odette Cancer Centre, Toronto, ON

11:30-12:15 **Lunch**

12:15-1:45 **WORKSHOPS**

**WORKSHOP 4** *Governor General*

**CHEST TUMOURS: CHALLENGES IN PRACTICE**

Patricia Tai, Conrad Falkson, Arjun Sahgal, Meredith Giuliani

OBJECTIVES: At the end of this workshop, the participants will be able to:

- ▮ Be competent on the application of various radiation treatment techniques, with respect to target volume definition and doses for different tumors in the chest, including mesothelioma and thymoma.
- ▮ Be familiar with re-irradiation treatment planning, and tolerance doses.
- ▮ Be aware of challenges in post-treatment imaging.

**WORKSHOP 5** *Toronto III*

**STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR SPINAL METASTASES**

Majed Alghamdi, Arjun Sahgal, Young Lee, Laura Masucci

OBJECTIVES: At the end of this workshop, the participants will be able to:

- ▮ Understand the indications, outcomes and toxicities of Spine SBRT.
- ▮ Know the surgical innovations in combination with SBRT.
- ▮ Describe target volumes, prescription dose and constraints for OARs.
- ▮ Evaluate SBRT plan.
- ▮ Know the QA process for spine SBRT.
- ▮ Understand SC24- Canadian Randomized Trial (20Gy /5 vs SBRT 24 Gy/2).

**WORKSHOP 6** *Tom Thomson*

**BUILDING A COMMUNITY OF PRACTICE THROUGH CARO TO PROMOTE QUALITY RADIOTHERAPY**

Amanda Caissie, Michael Brundage, Brian Liszewski, Christina Parsons, Gunita Mitera

OBJECTIVES: At the end of this workshop, the participants will be able to:

- | Understand what quality and best practice means for radiotherapy (RT).
- | Discuss examples of key quality improvement initiatives currently underway across Canadian RT centres and promoted through national organizations/ initiatives such as the Canadian Partnership for Quality Radiotherapy (CPQR) or National Peer Review Study.
- | Identify to the CARO Quality and Standards Committee for rationale for its creations.
- | Discuss how both academic and community Canadian RT centres could benefit from the committee as a community of practice (COP) driving RT QI initiatives.

1:45-2:45 **REVIEWERS' CHOICE** *Toronto I*

Moderators: Marc Gaudet, Paris-Ann Ingledew

OBJECTIVES: At the end of this session, the participants will be able to:

- | Understand a variety of interesting and select topics of radiation therapy innovations, quality of care, and quality of life measurements and how these
- | Impact our cancer population.

**87 INDIVIDUAL PATIENT DATA META-ANALYSIS OF KIDNEY SBRT: A REPORT FROM THE INTERNATIONAL RADIOSURGERY ONCOLOGY CONSORTIUM FOR KIDNEY (IROCK)** Alexander Louie<sup>1</sup>, Alexander Muacevic<sup>2</sup>, Michael Staehler<sup>2</sup>, Andrew Warner<sup>3</sup>, Senthilkumar Gandhihasan<sup>4</sup>, Lee Ponsky<sup>5</sup>, Rodney Ellis<sup>5</sup>, Irving Kaplan<sup>6</sup>, Anand Mahadevan<sup>6</sup>, William Chu<sup>7</sup>, Hiroshi Onishi<sup>8</sup>, Simon Lo<sup>9</sup>, Bin Teh<sup>10</sup>, Anand Swaminath<sup>11</sup>, Rohann Correa<sup>12</sup>, Shankar Siva<sup>4</sup>; <sup>1</sup>London Regional Cancer Program, London, ON; <sup>2</sup>University of Munich, Munich, Germany; <sup>3</sup>London Health Sciences Centre, London, ON; <sup>4</sup>University of Melbourne, Melbourne, Australia; <sup>5</sup>Case Western Reserve University, Cleveland, OH; <sup>6</sup>Harvard University, Boston, MA; <sup>7</sup>University of Toronto, Toronto, ON; <sup>8</sup>University of Yamanashi, Yamanashi, Japan; <sup>9</sup>University of Washington, Seattle, WA; <sup>10</sup>Weil Cornell Medical College, Houston, TX; <sup>11</sup>McMaster University, Hamilton, ON; <sup>12</sup>University of Western Ontario, London, ON

**88 A PROSPECTIVE PHASE II TRIAL OF TRANSPERINEAL ULTRASOUND GUIDED BRACHYTHERAPY FOR LOCALLY RECURRENT PROSTATE CANCER AFTER EXTERNAL BEAM RADIOTHERAPY (NRG/RTOG 0526)** Juanita Crook<sup>1</sup>, Peixin Zhang<sup>2</sup>, Thomas Pisansky<sup>3</sup>, Edouard Trabulsi<sup>4</sup>, Mahul Amin<sup>5</sup>, William Bice<sup>6</sup>, Gerard Morton<sup>7</sup>, Nadeem Pervez<sup>8</sup>, Eric Vigneault<sup>9</sup>, Jeff Michalski<sup>10</sup>, Charles Catton<sup>7</sup>, Mack Roach<sup>11</sup>, David Beyer<sup>12</sup>, Peter Rossi<sup>13</sup>, Eric Horitz<sup>14</sup>, Viroon Donovanik<sup>15</sup>, Chistiana Care<sup>15</sup>, Howard Sandler<sup>5</sup>; <sup>1</sup>University of British Columbia, Kelowna, BC; <sup>2</sup>New Jersey Institute of Technology, Philadelphia, PA; <sup>3</sup>University of Rochester, Rochester, MN; <sup>4</sup>Thomas Jefferson University, Philadelphia, PA; <sup>5</sup>Cedars-Sinai Medical Center, Los Angeles, CA; <sup>6</sup>John Muir Health Systems, Walnut Creek, CA; <sup>7</sup>University of Toronto, Toronto, ON; <sup>8</sup>University of Calgary, Calgary, AB; <sup>9</sup>Centre Hospitalier Universite de Quebec, Quebec, QC; <sup>10</sup>Washington University, St Louis, MO; <sup>11</sup>UCSF, San Francisco, CA; <sup>12</sup>Cancer Center of Northern Arizona, Scottsdale, AZ; <sup>13</sup>Emory University, Atlanta, GA; <sup>14</sup>Fox Chase, Philadelphia, PA; <sup>15</sup>Newark, DE



**89 A PILOT STUDY OF SALVAGE HDR BRACHY THERAPY IN PATIENTS WITH RECURRENT PROSTATE CANCER AFTER PRIMARY RADIATION: TOXICITY PROFILE AND OUTCOMES**

William Foster<sup>1</sup>, Eric Vigneault<sup>2</sup>, Marie-Claude Lavallée<sup>2</sup>, André-Guy Martin<sup>2</sup>;

<sup>1</sup>CHUQ Hotel-Dieu de Quebec, Québec, QC;

<sup>2</sup>Université Laval, Québec, QC

**90 THE USE OF CHEMOTHERAPY IN PLACE OF RADIOTHERAPY DOES NOT RESULT IN A LOWER INCIDENCE OF SECOND CANCERS IN PATIENTS WITH EARLY STAGE SEMINOMA: A POPULATION BASED STUDY IN BRITISH COLUMBIA**

Gaurav Bahl<sup>1</sup>, Rima Pathak<sup>1</sup>, Jenny Ko<sup>1</sup>, Michael Sia<sup>1</sup>, Christian Kollmannsberger<sup>2</sup>, Scott Tyldesley<sup>2</sup>;

<sup>1</sup>British Columbia Cancer Agency, Abbotsford, BC;

<sup>2</sup>British Columbia Cancer Agency, Vancouver, BC

**91 RADIOTHERAPY QUALITY ASSURANCE OF CONCURRENT CHEMO- RADIOTHERAPY IN PROCLAIM PHASE III TRIAL**

Anthony Brade<sup>1</sup>, Frederik Wenz<sup>2</sup>, Friederike Koppe<sup>3</sup>, Yolande Lievens<sup>4</sup>, Belen San Antonio<sup>5</sup>, Neill Iscoe<sup>6</sup>, Anwar Hossain<sup>7</sup>, Nadia Chouaki<sup>8</sup>, Suresh Senan<sup>9</sup>;

<sup>1</sup>Peel Regional Cancer Centre, Mississauga, ON;

<sup>2</sup>University Hospital Mannheim, Mannheim, Germany;

<sup>3</sup>Institute Verbeeten, Tilburg, Netherlands;

<sup>4</sup>Ghent University Hospital, Ghent, Belgium;

<sup>5</sup>Lilly España, Madrid, Spain;

<sup>6</sup>Eli Lilly Canada Inc., Toronto, ON;

<sup>7</sup>Eli Lilly and Company, Indianapolis, IN;

<sup>8</sup>Eli Lilly and Company, Neuilly-sur-Seine, France;

<sup>9</sup>VU University Medical Center, Amsterdam, Netherlands

**92 OPTIMAL IMAGING FOLLOW-UP SCHEDULES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY FOR EARLY NON-SMALL-CELL LUNG CANCER: FINDINGS OF AN INTERNATIONAL DELPHI CONSENSUS STUDY**

Timothy Nguyen<sup>1</sup>, Suresh Senan<sup>2</sup>, Jeffery Bradley<sup>3</sup>, Kevin Franks<sup>4</sup>, Meredith Giuliani<sup>5</sup>, Matthias Guckenberger<sup>6</sup>, Mark Landis<sup>7</sup>, Billy Loo Jr<sup>8</sup>, Alexander Louie<sup>6</sup>, Hiroshi Onishi<sup>9</sup>, Heidi Schmidt<sup>10</sup>, Robert Timmerman<sup>11</sup>, Gregory Videtic<sup>12</sup>, David Palma<sup>7</sup>;

<sup>1</sup>London Health Sciences Centre, London, ON;

<sup>2</sup>VU University Medical Center, Amsterdam, Netherlands;

<sup>3</sup>Washington University, St Louis, MO;

<sup>4</sup>Leeds University, Leeds, United Kingdom;

<sup>5</sup>Princess Margaret Cancer Centre, Toronto, ON;

<sup>6</sup>University Hospital Wuerzburg, Wuerzburg, Germany;

<sup>7</sup>London Health Sciences Centre, London, ON;

<sup>8</sup>Stanford University School of Medicine, Stanford, CA;

<sup>9</sup>University of Yamanashi, Yamanashi, Japan;

<sup>10</sup>Women's College Hospital, Toronto, ON;

<sup>11</sup>University of Texas Southwestern Medical Center, Dallas, TX;

<sup>12</sup>Cleveland Clinic, Cleveland, OH

2:45-3:00 **Keynote** *Toronto I*

Introduction: Fabio Cury

Beyond Medicine – The Human Touch, Life of Professionals!

Shelly Dev

3 :00-3 :15 **CLOSING REMARKS** *Toronto I*